China Health Technology Group bolsters board with two new director appointments

China Bozza Development Holdings Limited ( (HK:1069) ) has provided an announcement.

China Health Technology Group Holding Company Limited has strengthened its leadership team with the appointment of Ms. Cao Xiying as an executive director effective 15 January 2026, bringing project management and sales and marketing experience from internet finance and media technology sectors; she will serve an initial one-year term with remuneration aligned to market levels. The company has also named Mr. Li Liangjie as an independent non-executive director, adding over 15 years of sales management expertise and nearly a decade of online marketing experience in the health and wellness industry, including his role at Henan Yuhuan Health Technology Group; these appointments are expected to enhance the board’s governance, marketing capabilities and sector-specific insight, while ensuring compliance with Hong Kong listing requirements on board and committee composition.

The most recent analyst rating on (HK:1069) stock is a Hold with a HK$0.45 price target. To see the full list of analyst forecasts on China Bozza Development Holdings Limited stock, see the HK:1069 Stock Forecast page.

More about China Bozza Development Holdings Limited

China Health Technology Group Holding Company Limited, listed in Hong Kong, operates through subsidiaries in the health technology space, with a focus on health and wellness–related services and products, supported by expertise in online marketing, sales management and remote health services through its wider industry network.

Average Trading Volume: 381,230

Technical Sentiment Signal: Strong Sell

Current Market Cap: HK$42.71M

See more insights into 1069 stock on TipRanks’ Stock Analysis page.